Table 2.
Pathogens | Antibiotics | Trend for susceptibility | Correlation analysis | |||||
---|---|---|---|---|---|---|---|---|
r | p | Trend | Antibiotic in consumption | r | p | Correlation | ||
Escherichia coli | Imipenem | 0.073 | 0.840 | Stable | Carbapenems | −0.216 | 0.549 | No correlation |
SCF | −0.530 | 0.115 | Stable | 3GCs/β-lactamase inhibitorsa | −0.639 | 0.064 | No correlation | |
Ceftazidime | 0.665 | 0.051 | Stable | 3GC sensitive to paeb | 0.488 | 0.182 | No correlation | |
Klebsiella pneumoniae | Imipenem | −0.642 | 0.046 | Decreasing | Carbapenems | −0.649 | 0.042 | Negative |
SCF | −0.740 | 0.014 | Decreasing | 3GCs/β-lactamase inhibitorsa | −0.708 | 0.033 | Negative | |
Ceftazidime | 0.347 | 0.360 | Stable | 3GC sensitive to paeb | 0.511 | 0.160 | No correlation | |
Acinetobacter baumannii | Imipenem | −0.056 | 0.878 | Stable | Carbapenems | 0.077 | 0.832 | No correlation |
SCF | −0.783 | 0.007 | Decreasing | 3GCs/β-lactamase inhibitorsa | −0.775 | 0.014 | Negative | |
Ceftazidime | −0.267 | 0.488 | Stable | 3GC sensitive to paeb | −0.322 | 0.398 | No correlation | |
Pseudomonas aeruginosa | Imipenem | 0.167 | 0.644 | Stable | Carbapenems | −0.045 | 0.901 | No correlation |
SCF | 0.387 | 0.269 | Stable | 3GCs/β-lactamase inhibitorsa | −0.064 | 0.870 | No correlation | |
Ceftazidime | −0.488 | 0.152 | Stable | 3GC sensitive to paeb | −0.477 | 0.163 | No correlation | |
Staphylococcus aureus | Linezolid | 0.410 | 0.274 | Stable | Linezolid | 0.228 | 0.555 | No correlation |
Vancomycin | Maintained 100% | Glycopeptides | / | / | No correlation | |||
Coagulase-negative staphylococcus | Linezolid | −0.275 | 0.473 | Stable | Linezolid | −0.281 | 0.464 | No correlation |
Vancomycin | Maintained 100% | Glycopeptides | / | / | No correlation | |||
Enterococcus faecium | Linezolid | −0.320 | 0.401 | Stable | Linezolid | 0.098 | 0.802 | No correlation |
Vancomycin | 0.925 | <0.001 | Increasing | Glycopeptides | 0.633 | 0.049 | Positive | |
Enterococcus faecalis | Linezolid | 0.483 | 0.188 | Stable | Linezolid | 0.122 | 0.754 | No correlation |
Vancomycin | 0.735 | 0.015 | Increasing | Glycopeptides | 0.752 | 0.012 | Positive |
Note: aSince the consumption of 3GCs/β-lactamase inhibitors increased remarkably among 3GCs and SCF belongs to 3GCs/β-lactamase inhibitors, the correlation was conducted between the corresponding susceptibility and consumption. bSince the consumption of 3GCs sensitive to pae increased remarkably among 3GCs and ceftazidime belongs to this antibiotic type, the correlation was conducted between the corresponding susceptibility and consumption.
Abbreviations: 3GCs, third-generation cephalosporins; pae, P. aerugino; SCF, cefoperazone/sulbactam.